Clinical Significance of a Multicancer Screening Trial With Stage-Based End Points

How should the scientific community judge the clinical significance of the first randomized multicancer screening trial with its stage-based end point?This independent decision-analytic model study with 2 simulated cohorts of 70 000 participants estimated that the trial may achieve a 6% to 23% reduction in late-stage incidence over 3 years and a 6% to 9% reduction in cancer mortality over 5 years, with lung and colorectal cancers contributing the most to these reductions.These estimates challenge the research community to weigh the clinical significance of short-term, stage-based end points and to recognize the importance of sufficiently detailed reporting of test performance and outcomes by cancer type.

Corresponding Author: Ruth Etzioni, PhD, Division of Public Health Sciences, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, M3-B232, Seattle, WA 98109 (retzioni@fredhutch.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.